By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing firm Signal Genetics has agreed to buy molecular diagnostics company ChipDx for an undisclosed amount.

Under the terms of the deal announced today, Signal will acquire all of ChipDx's assets, including its patents for its prognostic tests for lung, breast, and colon cancers. It is buying BreastGeneDX, ColonGeneDX, and LungGeneDX, as well as all diagnostic and prognostic tests under development by ChipDx.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.